Webinar Home Page
Integrating Immune Therapies & Targeted Therapies Into Standards of Care for Solid and Hematologic Malignancies
December 10, 2016 – December 10, 2017
Click below to view
Gregory J. Riely, MD, PhD H. Jack West, MD
Webinar #4129a
DEBATE 1: Checkpoint antibodies are interchangeable regardless of PD-L1 status?
H. Jack West, MD
Gregory J. Riely, MD, PhD
Edward Garon, MD
Webinar #4129b
Managing squamous and adenocarcinoma NSCLC patients who fail or relapse on checkpoint inhibition: What are the options with immune therapy, targeted therapy and chemotherapy?
Edward Garon, MD
Gregory J. Riely, MD, PhD
Webinar #4129c
Strategies for managing NSCLC patients with acquired resistance (AR) to EGFR and ALK targeted therapy: What are the new standards of care? How does a clinician decide among five new EGFR agents for managing AR? What are the roles of immune therapy? liquid biopsies? NGS testing?
Gregory J. Riely, MD, PhD
Heather A. Wakelee, MD
Webinar #4129d
The ever expanding number of actionable NSCLC mutations? How do we best address this issue with NGS testing and other emerging issues?
Heather A. Wakelee, MD
Roy S. Herbst, MD, PhD
Webinar #4129e
Combination Strategies: What are the optimal strategies to combine immune therapies plus targeted therapies, and immune therapies with other immune therapies or chemotherapies?
Roy S. Herbst, MD, PhD
Mario Sznol, MD Jeffrey S. Weber, MD, PhD
Webinar #4129f
DEBATE 2: Should targeted therapy or Immune-oncology therapy be used for treatment-naive BRAF-mutated metastatic melanoma?
Mario Sznol, MD
Jeffrey S. Weber, MD, PhD
Jeffrey S. Weber, MD, PhD
Webinar #4129g
BRAF Wild type melanoma: What should be the first-line therapy for these patients: single-agent anti-PD-1 versus single-agent anti-CTLA4, oncoloytic viral therapy, versus their combination?
Jeffrey S. Weber, MD, PhD
Mario Sznol, MD
Webinar #4129h
Combinations and Sequencing of Immune therapy and/or targeted therapy: Matching patients and therapy
Mario Sznol, MD
Marianne Davies, DNP, ACNP, AOCNP
Webinar #4129k
The Role of the Nurse and Nurse Practitioner with Targeted and Immunotherapy for Cancer
Marianne Davies, DNP, ACNP, AOCNP
Jim M. Koeller, MS
Webinar #4129l
Can a Clinical Value be Established for Immunotherapies?
Jim M. Koeller, MS
Ranjana H. Advani, MD
Webinar #4129k
Scientific Rationale for Immunotherapy in Lymphoma: What are the current and emerging clinical applications?
Ranjana H. Advani, MD
Ranjana H. Advani, MD Philippe Armand, MD, PhD
Webinar #4129l
DEBATE 1: Checkpoint antibodies are interchangeable regardless of PD-L1 status?
Ranjana H. Advani, MD
Philippe Armand, MD, PhD
Philippe Armand, MD, PhD
Webinar #4129m
Checkpoint Blockade in Lymphoma
Philippe Armand, MD, PhD
Stanley R. Riddell, MD
Webinar #4129n
The emerging clinical applications of immune therapy for leukemia: From CAR-T cells and other potential game-changing strategies
Stanley R. Riddell, MD
John M. Pagel, MD, PhD Dsc
Webinar #4129o
Clinical Applications of Targeted Therapies and Immune Therapies for Leukemia: Is a New paradigm Emerging?
John M. Pagel, MD, PhD Dsc
Jeffrey Wolf, MD
Webinar #4129p
Multiple Myeloma: Expanding the Therapeutic Options by Targeting SLAMF7, CD38, Checkpoint Inhibition and Other Targets with Immune or Targeted Therapy various combinations
Jeffrey Wolf, MD
Daniel P. Petrylak, MD
Webinar #4129q
G/U Malignancies: Bladder Cancer, Renal Cell Cancer, Prostate Cancer: Monotherapy, Combination Immune therapy and/or Targeted therapy-Checkpoint inhibition, Immunomodulatory & Vaccine strategies
Daniel P. Petrylak, MD
Margaret A. Tempero, MD Eileen M. O'Reilly, MD
Webinar #4129r
DEBATE 4: Targeted therapy versus Immune Therapy for pancreatic cancer
Margaret A. Tempero, MD
Eileen M. O'Reilly, MD
Eileen M. O'Reilly, MD
Webinar #4129s
Pancreatic Cancer: Applying the advances with translational biology strategies using novel immune and targeted therapies: How do we optimally integrate all of these new strategies?
Eileen M. O'Reilly, MD
Corey J. Langer, MD
Webinar #4129t
H&N Cancer: Integrating Targeting the immune system with chemotherapy and targeted therapy
Corey J. Langer, MD